Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBIT (2022 - 2025)

Historic EBIT for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$53.8 million.

  • Centessa Pharmaceuticals' EBIT fell 1591.42% to -$53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year decrease of 3225.86%. This contributed to the annual value of -$201.1 million for FY2024, which is 1738.18% down from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported EBIT of -$53.8 million as of Q3 2025, which was down 1591.42% from -$54.7 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' EBIT registered a high of -$30.8 million during Q1 2025, and its lowest value of -$74.6 million during Q4 2024.
  • Moreover, its 4-year median value for EBIT was -$47.0 million (2023), whereas its average is -$48.3 million.
  • Per our database at Business Quant, Centessa Pharmaceuticals' EBIT soared by 3127.28% in 2023 and then plummeted by 11200.75% in 2024.
  • Quarter analysis of 4 years shows Centessa Pharmaceuticals' EBIT stood at -$41.6 million in 2022, then grew by 15.44% to -$35.2 million in 2023, then crashed by 112.01% to -$74.6 million in 2024, then grew by 27.88% to -$53.8 million in 2025.
  • Its EBIT stands at -$53.8 million for Q3 2025, versus -$54.7 million for Q2 2025 and -$30.8 million for Q1 2025.